Vocimagene amiretrorepvec

Unassigned

New Medicines

Recurrent high-grade glioma - in combination with extended-release 5-fluorocytosine

Information

Advanced therapy medicinal product (ATMP) gene therapy
Tocagen
Tocagen

Development and Regulatory status

None
None
Phase III Clinical Trials
Yes
Yes

Category

Toca 511 is a retroviral replicating vector which selectively delivers the cytosine deaminase (CD) gene to dividing cancer cells. Cells which express the CD gene are able to convert oral flucytosine (Toca FC) into fluorouracil locally in the tumour.
The annual incidence of malignant glioma is 3-5 per 100,000 [1].
Recurrent high-grade glioma - in combination with extended-release 5-fluorocytosine
Intratumoural

Further information

Yes
To be confirmed